As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: November 26, 2012
by Science Codex:
All patients with Alzheimer’s disease (AD) lose brain cells, which leads to a shrinking, or atrophy, of the brain. But the pattern of gray matter loss is significantly different in men and women, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
“We found that the extent and distribution of regional gray matter volume loss in the brain was strongly influenced by gender,” said lead researcher Maria Vittoria Spampinato, M.D., associate professor of radiology at the Medical University of South Carolina in Charleston.
According to the Alzheimer’s Association, 5.4 million Americans have AD, the sixth-leading cause of death in the U.S. Currently, there is no cure for AD, which lends urgency to research efforts designed to better understand, diagnose and treat this devastating illness.
“There is a strong interest in using magnetic resonance imaging (MRI) to assess brain atrophy with the purpose of monitoring dementia progression noninvasively and to aid in understanding which factors can influence brain atrophy progression and distribution in the Alzheimer’s brain,” Dr. Spampinato said.
In the study, Dr. Spampinato and colleagues analyzed data on 109 patients, including 60 men and 49 women (mean age 77), who participated in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a major study that followed hundreds of cognitively healthy individuals and individuals with mild cognitive impairment (MCI) and AD over a period of five years.
During the five-year period, each of the 109 patients progressed from amnestic MCI (in which the patient suffers memory loss but maintains cognitive function) to AD. Using MR images of the patients’ brains taken when they were diagnosed with AD and 12 months before and after the diagnosis, the researchers created brain maps that illustrated gray matter changes.
The brain maps revealed that compared to male patients, the women had greater atrophy in gray matter 12 months prior to their AD diagnosis and at the time of their diagnosis. The brain maps also showed that the men and women in the study lost gray matter volume in different areas of the brain as their disease progressed from MCI to AD.
“The female patients in our study initially had more gray matter atrophy than the male patients but over time, the men caught up,” Dr. Spampinato said. “In the men, the disease developed more aggressively in a shorter period of time.”
Dr. Spampinato said the gender differences in atrophy patterns have important implications for the development of therapies for MCI and AD.
“These differences should be taken into consideration when testing new drugs in clinical trials,” she said. “Knowing the difference between the male and female patterns of atrophy will help researchers better decipher a patient’s response to drug therapy.”
A new comprehensive study from Florida State University (FSU) finds no evidence to support the idea that personality changes begin before the clinical onset of mild cognitive impairment (MCI) or dementia. MCI is an intermediate...
On the evening of Monday November 27th, join us for conversation and cocktails with award-winning journalist, editor and author Tina Brown, and Indigo’s CEO Heather Reisman. Hear from Tina Brown about her eight-year tenure at Vanity...
The presence of TAR DNA-binding protein 43 (TDP-43) in the hippocampus on postmortem examination is associated with increased rates of hippocampal atrophy in patients with Alzheimer’s disease (AD), new research suggests. This association was greatest...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.